PULSE the living trend engine
🤖 Open Intelligence Dossier available for AI agents & citation View Markdown (.md) →
◼ Archived Business

RFK Jr.’s HHS Is Allowing These 6 Unapproved Peptides To Be Sold

HHS Secretary Robert F. Kennedy Jr. announced a new policy allowing licensed pharmacies and physicians to compound six unapproved peptides.

8sources
8articles
6velocity
+102%since first seen
9d agofirst detected

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

The brief

A new interim enforcement-discretion policy issued by the U.S. Department of Health and Human Services (HHS), announced by Secretary Robert F. Kennedy Jr., permits licensed pharmacies and physicians to compound six unapproved peptides, as reported by Forbes, Findlay News, and other outlets. Often referred to as the "Kennedy 6," the substances are BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500. According to Karen L. Kier writing for Findlay News, these short chains of amino acids are promoted by fitness enthusiasts, anti-aging clinics, and social media influencers for faster injury recovery, better sleep, enhanced energy, weight management, and longevity. Unlike FDA-approved peptide-based drugs such as insulin and GLP-1s, the "Kennedy 6" lack extensive human clinical evidence, with enthusiasm largely driven by animal research, laboratory studies, and testimonials. According to BioSpace, companies like Elysium Health and Amble Health are expanding access to these six peptides under the new policy. Elysium announced plans to offer them through Elysium Health Rx and launched research programs including the TIME-PEP study. The HHS interim policy directs the government not to pursue certain federal enforcement against licensed pharmacies and physicians that compound these six peptides, provided they follow safeguards like patient-specific prescriptions, traceable ingredients, and quality testing. However, sources note that this enforcement discretion does not constitute FDA approval. FDA staff scientists have strongly opposed the release of these peptides due to the lack of reliable human data and potential risks such as allergic reactions, contamination, and inaccurate dosing. Healio reports that physicians prescribing unapproved peptides still face significant regulatory, civil, and criminal risks, particularly if they utilize bulk drug substances not deemed safe by the FDA. Furthermore, state-level hurdles remain. As Findlay News reported, state boards of pharmacy retain independent authority, and Ohio already has regulations prohibiting pharmacists from compounding substances like BPC-157, meaning federal policy cannot override state laws.

Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 8d ago.

Quick answers

What are the six unapproved peptides allowed under the new HHS policy?

The six peptides, often called the "Kennedy 6," are BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500, according to Findlay News and BioSpace.

Does the new HHS enforcement-discretion policy mean the FDA approved these peptides?

No. According to Findlay News and BioSpace, enforcement discretion is not FDA approval, and compounded drugs are not reviewed by the FDA for safety, effectiveness, or quality.

Can state laws override the federal HHS peptide policy?

Yes. According to Findlay News and Healio, state boards of pharmacy and state attorneys general have authority to take independent enforcement actions under state laws, and federal policy does not override state restrictions such as those in Ohio.

Coverage (8)

Topics

Related trends

▲ Peaking Business

The GLP-1 boom has a dark side

FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.

5 sources 5 articles v 14 1d ago
\n \n \n \n \n \n \n